You are here
Canada House Wellness Group Inc. Accelerates Phenotyping of 62 In-House Genetics
TORONTO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE:CHV) and Abba Medix Corp. (“Abba”), CHV’s wholly owned Licensed Producer has accelerated their phenotyping program utilizing their state-of-the-art controlled grow facility in Pickering.
Growing since May 8, 2018, Abba Medix Corp. currently has 62 strains in-house. “With our main production area fully online, we have accelerated our phenotyping program and will continue to build our genetics library. The pursuit of superior genetics will never stop at Abba. Our team knows what patients and recreational consumers expect, and we intend to deliver it,” said Riley McGee, President, Abba Medix Corp.
Utilizing its exclusive partnership with a leading European seed breeder, Abba has carefully curated a library of strains offering a wide range of cannabinoid profiles. Abba will be working closely with Canada House Clinics (CHC), leveraging their 12,000 plus patients and their proprietary Knalysis Technologies patient management software.
“Canada House’s vertical integration has been designed from day one to bring evidence-based strains to patients. With Canada House Clinic’s medical professionals and diverse patient base, our proprietary software and our state-of-the-art controlled grow facility, we are positioned to become leaders in cannabis genetics. 2019 will be a pivotal year for Canada House Wellness Group Inc. as we claim our spot as leaders in the space,” said Chris Churchill Smith, CEO, Canada House.
Working closely with CHC’s highly qualified staff, Abba seeks to better serve patients and further our understanding of cannabinoid profiles and their respective applications.
For further information, please contact:
Boom Capital Markets
Canada House Wellness Group Inc.
Chris Churchill-Smith, CEO
ABOUT CANADA HOUSE WELLNESS GROUP INC.
Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services through its clinics and licensed producer. Canada House is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For more information, please visit www.canadahouse.ca or www.sedar.com.
Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements.
Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.